Krever Inquiry

Krever Inquiry
Moxy · CC BY-SA 4.0 · source
Name	Krever Inquiry
Date	1993–1998
Jurisdiction	Canada
Commissioner	Justice Brian Dickson
Reported	1997

Krever Inquiry The Krever Inquiry was a Canadian royal commission into contaminated blood and blood products that examined transmission of HIV/AIDS and Hepatitis C through transfusions, plasma-derived therapies, and organ transplantation. Chaired by Justice Horace Krever—a retired judge whose mandate intersected with institutions such as Health Canada, Canadian Red Cross, and provincial health authorities—the inquiry connected public health crises with regulatory failures, corporate practices, and international plasma procurement. The report prompted reforms across Canadian Blood Services, provincial ministries of health, and legislative frameworks including standards influenced by the World Health Organization.

Background

The inquiry arose after scandals involving infected blood supplies in the 1980s and early 1990s that implicated actors like the Canadian Red Cross and private plasma firms such as Lederle Laboratories and Cutter Laboratories. High-profile cases involved recipients from institutions like Shoreham Hospital and community groups including patient associations for hemophilia and chronic liver disease. The crisis overlapped with global events including the AIDS epidemic, controversies at the Red Cross Blood Transfusion Service, and litigation against multinational corporations like Baxter International and AstraZeneca. International comparisons involved regulators such as the Food and Drug Administration and healthcare systems in United Kingdom, United States, and France. Public pressure came from advocacy organizations including the Canadian Hemophilia Society and legal actions in provincial superior courts.

Establishment and Mandate

The federal-provincial inquiry was established by Prime Minister Jean Chrétien and Health Minister Anne McLellan to investigate causes and assign responsibility for tainted blood, drawing on precedents set by commissions like the Royal Commission on the Economic Union and Development Prospects for Canada. The mandate required examination of roles played by institutions such as Health Canada, the Canadian Red Cross, provincial ministries (including Ontario Ministry of Health and Quebec Ministry of Health and Social Services), and private plasma companies like Alpha Therapeutic Corporation. The commission worked with legal counsel connected to courts such as the Supreme Court of Canada and consulted international experts from organizations like the Centers for Disease Control and Prevention and the European Medicines Agency.

Investigation and Findings

The inquiry conducted hearings with witnesses from the Canadian Red Cross, blood operators like the Canadian Blood Services precursor organizations, and corporations including Cutter Biological and Wellcome Foundation. Scientific testimony referenced research from laboratories at institutions such as McGill University, University of Toronto, and University of British Columbia, and engaged virologists affiliated with the National Institutes of Health and specialists from the Public Health Agency of Canada. Findings highlighted failures in donor screening systems used by blood operators, deficiencies in oversight by Health Canada, and ethical lapses by private suppliers including inadequate viral inactivation processes used by firms like Baxter International. The report detailed how plasma procurement chains tied to companies operating in regions including United States, Germany, and Philippines contributed to contamination. Legal scrutiny touched on negligence claims brought in provincial courts such as the Ontario Court of Appeal and regulatory enforcement under statutes analogized with the Food and Drugs Act.

Recommendations and Reforms

Recommendations led to the creation of new institutions and standards influenced by international agencies like the World Health Organization and best practices from the United Kingdom Blood Transfusion Service. The inquiry recommended establishing an independent national body modeled on organizations like Australian Red Cross Lifeblood and regulatory reforms within Health Canada to adopt stricter licensing and surveillance akin to measures by the European Medicines Agency. Policy changes affected procurement contracts with companies such as Cutter Laboratories and Baxter International, and prompted adoption of nucleic acid testing methods developed at research centers like Toronto General Hospital and SickKids Hospital. Legislative responses drew on frameworks used in other inquiries such as the Brittenham Inquiry and influenced provincial statutes in Ontario, Quebec, and Alberta. Compensation schemes were discussed with reference to precedents like the HIV Compensation Program in other jurisdictions.

Aftermath and Impact

The inquiry reshaped blood system governance, accelerating the transfer of blood services from the Canadian Red Cross to a new entity, Canadian Blood Services, and influenced the later creation of Héma-Québec. It affected relationships with multinational suppliers including Baxter International and prompted policy shifts in provincial ministries such as the Ontario Ministry of Health and Long-Term Care. The report informed litigation strategies in courts including the Supreme Court of Canada and settlements negotiated with advocacy groups like the Canadian Hemophilia Society and HIV/AIDS Legal Network. Internationally, the inquiry influenced standards in the European Union and prompted reviews by regulators like the Food and Drug Administration. Its legacy continues in academic studies at institutions such as McMaster University and Simon Fraser University and in public policy curricula referencing crisis inquiries like the Commission of Inquiry into the Blood System.

Category:Canadian inquiries